Should Brepocitinib's New Trials and Batoclimab's Setback Require Action From Roivant Sciences (ROIV) Investors? [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
eye disease, while also announcing that Priovant has begun a new seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, alongside ongoing late-stage programs and an FDA Priority Review for dermatomyositis. This mix of pipeline expansion into an underserved inflammatory scalp disorder with no approved therapies, coupled with regulatory momentum for brepocitinib despite a setback for batoclimab, highlights how Roivant's diversified immunology portfolio is increasingly concentrated in areas of high unmet clinical need. We'll now examine how the new late-stage brepocitinib program in lichen planopilaris reshapes Roivant's broader investment narrative and risk profile. Find 62 companies with promising cash flow potential yet trading below their fair value Roivant Sciences Investment Narrative Recap To own Roivant here, you need to believe its broad immunology pipeline can convert into commercial products despite ongoing losses and frequent trial readouts. In the near t
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Ohio governor: Vivek Ramaswamy faces little-known GOP challengers [USA TODAY]USA TODAY
- Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript [Seeking Alpha]Seeking Alpha
- Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript [Seeking Alpha]Seeking Alpha
- Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint [Yahoo! Finance]Yahoo! Finance
- Immunovant falls on late-stage trial setback for TED therapy [Seeking Alpha]Seeking Alpha
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 4/10/26 - Form 4
- 4/8/26 - Form 144
- 4/2/26 - Form 4
- ROIV's page on the SEC website